Explain this page
Arphra AIPlain-English read on AllianceBernstein Holding L.P.’s valuation06-10today
- AB Akola Group notification on transactions in the Company's securities by the person discharging managerial responsibilities7h
- AB Akola Group notification on transactions in the Company's securities by the person discharging managerial responsibilities7h
- Le brevet d’AB Science concernant le masitinib dans le traitement du cancer de la prostate métastatique hormono-résistant a été officiellement délivré aux Etats-Unis avec une durée de protection jusqu’en 204220h
- AB Science patent for masitinib in the treatment of metastatic castrate resistant prostate cancer formally granted in the United States with a protection until 204220h
AI Issuer Brief
Arphra AILoading cached brief…
Fair value
Football field →Weighted blend
$59.73
+65.19% vs spot
Recommendation
Strong Buy
19 of 20 methods
Method spread
10bull7bear
±5% threshold
Analyst PT consensus: $39.75 (+9.93%)
Candlestick · 1Y
Open in chart workstation →AB
36.03-13.97%H 43.79L 35.65MA50 37.78MA200 —Avg vol 387K
Price change · trailing returns
Live| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.80% | -0.82% | -5.86% | -3.60% | -7.80% | -6.03% | -9.33% | +10.41% | -16.41% | +56.88% | +1329.25% |
Insider · 30d
History →Bought
$0
0 txns
Sold
$0
0 txns
Net flow
+$0
Aftermarket
LiveLast trade
$35.53
1 sh
Bid
$33.78
30 sh
Ask
$37.28
1 sh
Spread
$3.500
Recent quarters
All financials →| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q1 Mar 2026 | $92.26M | $85.24M | $0.92 |
| Q4 Dec 2025 | $89.76M | $81.8M | $0.90 |
| Q3 Sep 2025 | $81.41M | $73.75M | $0.79 |
| Q2 Jun 2025 | $78.83M | $70.25M | $0.64 |
| Q1 Mar 2025 | $82.75M | $74.03M | $0.67 |
| Q4 Dec 2024 | $116.59M | $105.43M | $0.92 |
Sector & industry today
LiveSectors
- Utilities+3.33%
- Financial Services+0.02%
- Industrials-0.12%
- Healthcare-0.72%
- Energy-0.94%
- Technology-0.95%
- Consumer Defensive-1.52%
- Basic Materials-1.60%
- Consumer Cyclical-1.74%
- Communication Services-1.79%
- Real Estate-2.19%
Top industries (issuer's industry highlighted)
- Auto - Dealerships-6.22%
- Trucking-5.25%
- Renewable Utilities+5.11%
- Oil & Gas Energy-4.86%
- Consulting Services-4.82%
- Financial - Mortgages-4.15%
- REIT - Office-3.71%
- Software - Application-3.50%
- Medical - Healthcare Information Services-3.48%
- Grocery Stores-3.45%
- Discount Stores-3.44%
- REIT - Diversified-3.43%
Analyst view
Consensus target
—
No price-target data returned for this ticker.
Recent actions
0 ↑0 ↓0 hold
- No recent grade actions.
News
DB · news_items- AB Akola Group notification on transactions in the Company's securities by the person discharging managerial responsibilitiesglobenewswire.com·Jun 18, 2026
- AB Akola Group notification on transactions in the Company's securities by the person discharging managerial responsibilitiesglobenewswire.com·Jun 18, 2026
- Le brevet d’AB Science concernant le masitinib dans le traitement du cancer de la prostate métastatique hormono-résistant a été officiellement délivré aux Etats-Unis avec une durée de protection jusqu’en 2042globenewswire.com·Jun 17, 2026
- AB Science patent for masitinib in the treatment of metastatic castrate resistant prostate cancer formally granted in the United States with a protection until 2042globenewswire.com·Jun 17, 2026
- AB Science patent for masitinib in the treatment of metastatic castrate resistant prostate cancer formally granted in the United States with a protection until 2042globenewswire.com·Jun 17, 2026
- AB Science patent for masitinib in the treatment of metastatic castrate resistant prostate cancer formally granted in the United States with a protection until 2042globenewswire.com·Jun 17, 2026
- AB Announces May 31, 2026 Assets Under Managementprnewswire.com·Jun 10, 2026
- AB Announces May 31, 2026 Assets Under Managementprnewswire.com·Jun 10, 2026
Recent analyst activity
DB- Jun 08, 2026GradeOutperform → OutperformAllianceBernstein price target lowered to $40 from $42 at Evercore ISIBernstein
- Jun 08, 2026PT$40.00AllianceBernstein price target lowered to $40 from $42 at Evercore ISIEvercore ISI
- Jun 04, 2026GradeOverweight → OverweightMorgan Stanley Upgrades Savola Group (SAVOLA:AB) to OverweightMorgan Stanley
Peers
No peer list available for AB.
Total assets
$1.24B
Total debt
$0
Cash & equiv
$0
Operating CF
$352.37M
Free cash flow
$352.37M
Buybacks
$0
Recent insiders
All →| Insider | Action | Shares | Value | Date |
|---|---|---|---|---|
| No open-market insider activity in the recent window. | ||||
Income statement · annual
5y| Period | Revenue | Op income | Net income | EPS | Net margin |
|---|---|---|---|---|---|
| FY 2025 | $332.76M | $332.76M | $299.84M | $2.97 | +90.11% |
| FY 2024 | $461.95M | $461.95M | $423.37M | $3.71 | +91.65% |
| FY 2023 | $299.78M | $299.78M | $264.18M | $2.34 | +88.13% |
| FY 2022 | $305.5M | $305.5M | $274.17M | $2.69 | +89.74% |
| FY 2021 | $416.33M | $416.33M | $385.84M | $3.88 | +92.68% |